Baxter International Inc. (BAX) said Friday that it has launched full-scale production of a commercial vaccine for the A/H1N1 flu virus and that it could have it ready for use as early as July.
(...)
Other companies including GlaxoSmithKline Plc (GSK), Sanofi-Aventis (SNY) and Solvay SA (SOLB.BT) have also said they have received orders for or are ready to begin producing vaccines for swine flu.
As for GlaxoSmithKline, they also use the cell-based technology.
This fact is contrary to what has been reported in stories with Novartis...
So again, who had the orginal seed strain in Mexico and why did GlaxoSmithKline get the first contracts if it uses eggs to grow the strain?
The stories on GalxoSmithKline are B.S. My bet is they are now working on a new mutated strain of the H1N1...
London-based GlaxoSmithKline (NYSE: GSK), which has its U.S. headquarters in Research Triangle Park, said on Friday that it has begun the process of developing a new vaccine at manufacturing sites in Canada and Germany. The company expects the first doses of vaccine to be available in four to six months, subject to regulatory approval.
The fact that other companies are coming out ahead of GlaxoSmithKline would diminish the contract that was first placed with GlaxoSmithKline...
As I stated awhile back on a previous thread, why would governments contract with a company that would use a process that is, (when compared to other companies) months behind in developing a vaccine?
The fact is, Glaxo doesn't, it uses cell-based technology too.
So don't be too surprised to see news in the fall that the virus is spreading faster and the severity is getting stronger and a new vaccine is being developed...
Posts
No comments:
Post a Comment